Business
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s disease BETHESDA, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Gain
About this update from Gain Therapeutics, Inc.
[{"type":"text","content":"Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s disease\nBETHESDA, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late-breaking abstract with new data of GT-02287 in preclinical models of Parkinson’s disease has been accepted for a platform presentation at the 20th Annual WORLDSymposium™ being held February 4-9, 2024 in San Diego, CA. Details of the platform presentation are as follows: Title: GT-02287, a clinical stage GCase enhancer, displays neuroprotection and restores motor function in preclinical models of Parkinson’s disease following delayed administrationPresenter: Beatriz Calvo-Flores Guzman, Ph.D., Gain TherapeuticsSession: Late-Breaking ScienceDate and Time: Friday, February 9, 2024, 8:00 a.m. PTRegister: here About WORLDSymposium™ WORLDSymposium™ is an annual research conference dedicated to lysosomal diseases. WORLD is an acronym that stands for We’re Organizing Research on Lysosomal Diseases. The goal of WORLDSymposium is to provide an interdisciplinary forum to explore and discuss specific areas of interest, research and clinical applicability related to lysosomal diseases. Each year, WORLDSymposium hosts a scientific meeting presenting the latest information from basic science, translational research, and clinical trials for lysosomal diseases. About Gain Therapeutics, Inc. Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287, in development for the treatment of GBA1 Parkinson’s disease, is currently being evaluated in a Phase 1 clinical trial. Leveraging AI-supported structural biology, proprietary algorithms and supercomputer-powered physics-based models, the company’s SEE-Tx® discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is...